MINNEAPOLIS, Oct. 3, 2019 /PRNewswire/ -- Today, Bright Health announced details of its 2020 Medicare Advantage plans and pricing in New York City. Bright Health developed its plans through a collaboration with Mount Sinai Health Partners whose clinically integrated network coordinates effective and efficient care for more tha

SCHLIEREN, Switzerland and SAN FRANCISCO, Oct. 3, 2019 /PRNewswire/ -- Akero Therapeutics and InSphero AG today announced that Akero has selected InSphero's 3D InSight™ Human Liver Disease Platform to characterize the physiological effects of AKR-001 in different types of liver cells. AKR-001 is designed to be a novel, lon

VANCOUVER, British Columbia, Oct. 3, 2019 /PRNewswire/ -- Core One Labs Inc. (CSE: COOL), (OTCQX: CLABF), (Frankfurt: LD6, WKN: A14XHT) ("COOL" or the "Company") announces it has received a Provisional Nursery License for Core Isogenics Inc.Core Isogenics Inc. received a yearly renewable Provisional Cultivation License issued

SAN DIEGO, Oct. 3, 2019 /PRNewswire/ -- Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced a restructuring to focus its resources on the clinical develop

LOS ANGELES, Oct. 3, 2019 /PRNewswire/ -- Winged, the first CBD product line formulated exclusively for women, announced today its pledge to donate $25,000 this year

TUCSON, Ariz., Oct. 3, 2019 /PRNewswire/ -- Accelerate Diagnostics, Inc. today announced presentation of full data from three outcome studies at IDWeek™ 2019. The full data being presented build upon the high-level findings that were first reported in the Company's September 18, 2019 press release.

YOQNEAM, Israel, Oct. 3, 2019 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, announced that it has completed the establishment of two new subsidiaries in the Asia Pacific region - InMode India, located in Delhi, and InMode Aust

AHMEDABAD, India, Oct. 3, 2019 /PRNewswire/ -- Zydus Cadila, an innovation-driven, global pharmaceutical company, announced that Saroglitazar Magnesium has achieved the primary end-points in the EVIDENCES IV trial in patients with NAFLD and NASH.The EVIDENCES IV NASH trial was a randomized, double-blind, placebo-controlled study that enrolled 106 pat

DUBLIN, Oct. 3, 2019 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced the relaunch of the AB rated generic equivalent of Transderm Scop® (scopolamine 1.5 mg). Annual market sales of Transderm Scop® and therapeutic equivalents for the 12 months ending August 2019 were approximately

BOSTON, Oct. 3, 2019 /PRNewswire/ -- Blue Cross Blue Shield of Massachusetts ("Blue Cross") today announced that it will offer